Safety assessment of omeprazole use: A review
dc.contributor.author | Forgerini, Marcela [UNESP] | |
dc.contributor.author | Mieli, Stephania [UNESP] | |
dc.contributor.author | Mastroianni, Patrícia de Carvalho [UNESP] | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2019-10-06T17:05:59Z | |
dc.date.available | 2019-10-06T17:05:59Z | |
dc.date.issued | 2018-01-01 | |
dc.description.abstract | BACKGROUND: Risks regarding hospital admission due to adverse drug reactions and drug interactions from use of omeprazole have been reported. The question guiding the present review was “Which adverse events occur in patients using omeprazole in a Food and Drug Administration-approved and/or off-label manner? It was also proposed to evaluate the safety of use of omeprazole. DESIGN AND SETTING: Qualitative narrative review with critical evaluation, in a public university. METHODS: The PubMed, SCOPUS, LILACS, SciELO, EMBASE and EBSCO databases were searched on July 31, 2018. Studies evaluating adverse events were screened. RESULTS: 72 articles were included, among which 58 reported on adverse drug events (47, adverse drug reactions; 5, drug interactions; and 6, situations of ineffectiveness). 28 adverse drug reactions not described in compendia and drug leaflets were described in these studies: myocardial infarction (6); stroke (2); spontaneous abortion (1); proliferative changes (1); chills (1); heart failure (1); thrombosis (2); and dementia (1), among others. Severe adverse reactions, for instance cardiac problems, Steven-Johnson syndrome and proliferative changes, were identified. The antiplatelet effects of drugs such as clopidogrel, in patients who underwent heart-related surgery, increased the risk of developing cardiac problems, such as cardiovascular death, myocardial infarction and stroke. In newly transplanted patients, decreased absorption of mycophenolate mofetil occurred, thus leading to rejection of transplanted organs. CONCLUSION: Use of omeprazole should be monitored primarily in patients with heart disorders using antiplatelet agents concomitantly, and in newly transplanted patients using mycophenolic acid, in order to avoid serious adverse reactions. | en |
dc.description.affiliation | Universidade Estadual Paulista (UNESP) | |
dc.description.affiliation | Department of Drugs and Medicines Universidade Estadual Paulista (UNESP) | |
dc.description.affiliationUnesp | Universidade Estadual Paulista (UNESP) | |
dc.description.affiliationUnesp | Department of Drugs and Medicines Universidade Estadual Paulista (UNESP) | |
dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.description.sponsorship | Universidade Estadual Paulista | |
dc.description.sponsorshipId | CNPq: 131206/2017-6 | |
dc.description.sponsorshipId | FAPESP: 2013/12681-2 | |
dc.description.sponsorshipId | FAPESP: 2014/03468-6 | |
dc.format.extent | 557-570 | |
dc.identifier | http://dx.doi.org/10.1590/1516-3180.2018.0019220318 | |
dc.identifier.citation | Sao Paulo Medical Journal, v. 136, n. 6, p. 557-570, 2018. | |
dc.identifier.doi | 10.1590/1516-3180.2018.0019220318 | |
dc.identifier.file | S1516-31802018000600557.pdf | |
dc.identifier.issn | 1516-3180 | |
dc.identifier.scielo | S1516-31802018000600557 | |
dc.identifier.scopus | 2-s2.0-85063259178 | |
dc.identifier.uri | http://hdl.handle.net/11449/190214 | |
dc.language.iso | eng | |
dc.relation.ispartof | Sao Paulo Medical Journal | |
dc.rights.accessRights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | Drug interactions | |
dc.subject | Drug-related side effects and adverse reactions | |
dc.subject | Proton pump inhibitors | |
dc.subject | Review | |
dc.subject | Treatment outcome | |
dc.title | Safety assessment of omeprazole use: A review | en |
dc.type | Resenha | |
unesp.author.orcid | 0000-0002-2905-8519[1] | |
unesp.author.orcid | 0000-0001-5002-966X[2] | |
unesp.author.orcid | 0000-0001-8467-7278[3] | |
unesp.department | Fármacos e Medicamentos - FCF | pt |
Arquivos
Pacote Original
1 - 1 de 1
Carregando...
- Nome:
- S1516-31802018000600557.pdf
- Tamanho:
- 247.29 KB
- Formato:
- Adobe Portable Document Format